Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
Related Experiment Video
Updated: Apr 11, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Junko Tanizaki1, Dalia Ercan1, Marzia Capelletti1
1Lowe Center for Thoracic Oncology, Boston, Massachusetts. Department of Medical Oncology, Boston, Massachusetts.
Abstract:
The discovery of oncogenic driver mutations and the subsequent developments in targeted therapies have led to improved outcomes for subsets of lung cancer patients. The identification of additional oncogenic and drug-sensitive alterations may similarly lead to new therapeutic approaches for lung cancer. We identify and characterize novel FGFR2 extracellular domain insertion mutations and demonstrate that they are both oncogenic and sensitive to inhibition by FGFR kinase inhibitors. We demonstrate that the mechanism of FGFR2 activation and subsequent transformation is mediated by ligand-independent dimerization and activation of FGFR2 kinase activity. Both FGFR2-mutant forms are predominantly located in the endoplasmic reticulum and Golgi but nevertheless can activate downstream signaling pathways through their interactions with fibroblast growth factor receptor substrate 2 (FRS2). Our findings provide a rationale for therapeutically targeting this unique subset of FGFR2-mutant cancers as well as insight into their oncogenic mechanisms.
Insights
Novel FGFR2 mutations drive lung cancer through ligand-independent dimerization. These oncogenic FGFR2 alterations are sensitive to FGFR kinase inhibitors, offering new therapeutic targets for lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted therapies based on oncogenic driver mutations have improved lung cancer patient outcomes.
- Identifying new drug-sensitive alterations is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To identify and characterize novel FGFR2 extracellular domain insertion mutations in lung cancer.
- To investigate the oncogenic potential and therapeutic sensitivity of these FGFR2 mutations.
Main Methods:
- Identification and characterization of FGFR2 mutations.
- Assessment of oncogenic activity and drug sensitivity.
- Mechanistic studies involving dimerization, kinase activity, and downstream signaling.
Main Results:
- Novel FGFR2 extracellular domain insertion mutations were identified and characterized.
- These mutations were found to be both oncogenic and sensitive to FGFR kinase inhibitors.
- Ligand-independent dimerization and activation of FGFR2 kinase mediate oncogenesis.
- Mutant FGFR2 localized to the ER and Golgi activates downstream signaling via FRS2.
Conclusions:
- FGFR2 extracellular domain insertion mutations represent a distinct subset of oncogenic lung cancer.
- These mutations provide a rationale for targeted therapy with FGFR kinase inhibitors.
- Understanding the oncogenic mechanisms of FGFR2 mutations offers insights for future treatment strategies.
More Related Videos
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...